I f channel inhibitor ivabradine lowers heart rate in mice with enhanced sympathoadrenergic activities

British Journal of Pharmacology

Volumn 142, Issue 1, 2004, Pages 107-112

  Du, Xiao Jun ^a   Feng, Xinheng ^a   Gao, Xiao Ming ^a   Tan, Tze Ping ^a   Kiriazis, Helen ^a   Dart, Anthony M ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Echocardiography; Sinus node inhibitor; Sympathetic nervous system; Transgenic mice

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ISOPRENALINE; IVABRADINE;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART DEPOLARIZATION; HEART LEFT VENTRICLE; HEART RATE; ION CURRENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; SINUS NODE; STRESS; SYMPATHETIC TONE; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BENZAZEPINES; CARDIAC PACING, ARTIFICIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; ION CHANNELS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, ADRENERGIC, BETA; SYMPATHETIC NERVOUS SYSTEM;

EID: 2542527721     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705696     Document Type: Article

References (35)

1. BOIS, P., BESCOND, J., RENAUDON, B. & LENFANT, J. (1996). Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br. J. Pharmacol., 118, 1051-1057.
2. 2-adrenoceptor. Nature, 374, 272-276.
3. f inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation, 107, 817-823.
4. BRISTOW, M. (2000). Mechanistic and clinical rationales for using β-blockers in heart failure. J. Card Fail., 6 (Suppl 1), 8-14.
5. f channels by ivabradine. J. Gen. Physiol., 120, 1-13.
6. CALDERONE, A., BOUVIER, M., LI, K., JUNEAU, C., DE CHAMPLAIN, J. & ROULEAU, J.L. (1991). Dysfunction of the β- and α-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog. Circ. Res., 69, 332-343.
7. CAMM, A. & LAU, C. (2003). Electrophysiological effects of a single intravenous administration of ivabradine (s 16257) in adult patients with normal baseline electrophysiology. Drugs Res. Dev., 4, 83-89.
8. CATTERALL, W.A., SCHEUER, T., THOMSEN, W. & ROSSIE, S. (1991). Structure and modulation of voltage-gated ion channels. Ann. N.Y. Acad. Sci., 625, 174-180.
9. CLELAND, J.G., BRISTOW, M.R., ERDMANN, E., REMME, W.J., SWEDBERG, K. & WAAGSTEIN, F. (1996). β Blocking agents in heart failure. Should they be used and how? Eur. Heart J., 17, 1629-1639.
10. COHN, J.N. (1990). Abnormalities of peripheral sympathetic nervous system control in congestive heart failure. Circulation, 82, 159-167.
11. COLIN, P., GHALEH, B., HITTINGER, L., MONNET, X., SLAMA, M., GIUDICELLI, J.F. & BERDEAUX, A. (2002). Differential effects of heart rate reduction and β-blockade on left ventricular relaxation during exercise. Am. J. Physiol., 282, H672-H679.
12. f) to generation of spontaneous activity in rabbit sino-atrial node myocytes. J. Physiol., 434, 23-40.
13. f) plays an important role in regulating SA node pacemaker activity. Cardiovasc. Res., 30, 307-308.
14. DIFRANCESCO, D., DUCOURET, P. & ROBINSON, R.B. (1989). Muscarinic modulation of cardiac rate at low acetylcholine concentrations. Science, 243, 669-671.
15. DIFRANCESCO, D. & TORTORA, P. (1991). Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature, 351, 145-147.
16. 2-adrenergic receptors in the heart. Cardiovasc. Res., 48, 448-454.
17. 2-adrenergic receptor. Am. J. Physiol., 271, H630-H636.
18. EMANUELI, C., MAESTRI, R., CORRADI, D., MARCHIONE, R., MINASI, A., TOZZI, M.G., SALIS, M.B., STRAINO, S., CAPOGROSSI, M.C., OLIVETTI, G. & MADEDDU, P. (1999). Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation, 100, 2359-2365.
19. 1-adrenergic receptor transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 96, 7059-7064.
20. GAO, X.M., DART, A.M., DEWAR, E., JENNINGS, G. & DU, X.J. (2000). Serial echocardiographic assessment of left ventricular dimensions and function after myocardial infarction in mice. Cardiovasc. Res., 45, 330-338.
21. GARDINER, S.M., KEMP, P.A., MARCH, J.E. & BENNETT, T. (1995). Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br. J. Pharmacol., 115, 579-586.
22. f current mediates β-adrenergic enhancement of heart rate but not contractility in vivo. Basic Res. Cardiol., 90, 192-202.
23. HARDT, S.E., GENG, Y.J., MONTAGNE, O., ASAI, K., HONG, C., YANG, G.P., BISHOP, S.P., KIM, S.J., VATNER, D.E., SEIDMAN, C.E., SEIDMAN, J.G., HOMCY, C.J. & VATNER, S.F. (2002). Accelerated cardiomyopathy in mice with overexpression of cardiac Gsα and a missense mutation in the α-myosin heavy chain. Circulation, 105, 614-620.
24. KAYE, D.M., LEFKOVITS, J., JENNINGS, G.L., BERGIN, P., BROUGHTON, A. & ESLER, M.D. (1995). Adverse consequences of high sympathetic nervous activity in the failing human heart. J. Am. Coll. Cardiol., 26, 1257-1263.
25. KLIPPERT, P., JEANNIOT, J.P., POLVE, S., LEFEVRE, C. & MERDJAN, H. (1998). Determination of ivabradine and its N-demethylated metabolite in human plasma and urine, and in rat and dog plasma by a validated high-performance liquid chromatographic method with fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl., 719, 125-133.
26. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation, 101, 1707-1714.
27. 2- adrenergic receptor. Science, 264, 582-586.
28. MONNET, X., GHALEH, B., COLIN, P., DE CURZON, O.P., GIUDICELLI, J.F. & BERDEAUX, A. (2001). Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J. Pharmacol. Exp. Ther., 299, 1133-1139.
29. NAGATSU, M., SPINALE, F.G., KOIDE, M., TAGAWA, H., DEFREITAS, G., COOPER, G.T. & CARABELLO, B.A. (2000). Bradycardia and the role of β-blockade in the amelioration of left ventricular dysfunction. Circulation, 101, 653-659.
30. PACKER, D.L., BARDY, G.H., WORLEY, S.J., SMITH, M.S., COBB, F.R., COLEMAN, R.E., GALLAGHER, J.J. & GERMAN, L.D. (1986). Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am. J. Cardiol., 57, 563-570.
31. PACKER, M., BRISTOW, M.R., COHN, J.N., COLUCCI, W.S., FOWLER, M.B., GILBERT, E.M. & SHUSTERMAN, N.H. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med., 334, 1349-1355.
32. SIMON, L., GHALEH, B., PUYBASSET, L., GIUDICELLI, J.F. & BERDEAUX, A. (1995). Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J. Pharmacol. Exp. Ther., 275, 659-666.
33. THOLLON, C., BIDOUARD, J.P., CAMBARRAT, C., LESAGE, L., REURE, H., DELESCLUSE, I., VIAN, J., PEGLION, J.L. & VILAINE, J.P. (1997). Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur. J. Pharmacol., 339, 43-51.
34. THOLLON, C., CAMBARRAT, C., VIAN, J., PROST, J.F., PEGLION, J.L. & VILAINE, J.P. (1994). Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br. J. Pharmacol., 112, 37-42.
35. YANG, X.P., LIU, Y.H., RHALEB, N.E., KURIHARA, N., KIM, H.E. & CARRETERO, O.A. (1999). Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am. J. Physiol., 277, H1967-H1974.